We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Omnitrope Application Faces Potential European Roadblock
Omnitrope Application Faces Potential European Roadblock
March 24, 2006
Sandoz’ application to market its generic human growth hormone Omnitrope may not meet the European Commission’s (EC) current regulatory pathway for follow-on biologics but is still likely to be approved, according to an expert.